Hansa Biopharma Year-end report January-December 2023:
· Strong revenue generation in Q4 2023 including SEK 43m in Idefirix® product sales supported by growth in new markets such as U.K., Germany, and Spain
· Encouraging results from first-in-human trial of HNSA-5487
· Initiation of phase 1b trial of imlifidase as pre-treatment to Sarepta's SRP-9001 in DMD
https://www.hansabiopharma.com/media/press-releases/2024/hansa-biopharma-year-end-report-january-december-2023/
· Strong revenue generation in Q4 2023 including SEK 43m in Idefirix® product sales supported by growth in new markets such as U.K., Germany, and Spain
· Encouraging results from first-in-human trial of HNSA-5487
· Initiation of phase 1b trial of imlifidase as pre-treatment to Sarepta's SRP-9001 in DMD
https://www.hansabiopharma.com/media/press-releases/2024/hansa-biopharma-year-end-report-january-december-2023/
2/2 2024 09:29 exitnu 0
118473 Hansa Biopharma will host a telephone conference Friday February 2, 2024, 14:00 CET / 8:00am EST.
The event will be hosted by Hansa Biopharma's CEO, Søren Tulstrup, CCO, U.S. President, Matthew Shaulis, CSO Hitto Kaufmann and CFO, Donato Spota. The presentation will be held in English.
The webcast will be available on https://hansabiopharma.eventcdn.net/events/fullyear2023
The event will be hosted by Hansa Biopharma's CEO, Søren Tulstrup, CCO, U.S. President, Matthew Shaulis, CSO Hitto Kaufmann and CFO, Donato Spota. The presentation will be held in English.
The webcast will be available on https://hansabiopharma.eventcdn.net/events/fullyear2023
